Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com
Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biotechnology company's stock.
證券新聞網啟動對股份的覆蓋 卡利瑟拉生物科學 (納斯達克:卡拉 — 獲得評級) 在星期六發給投資者的研究報告中。該經紀公司對該生物技術公司的股票發出了持有評級。
CALA has been the topic of several other research reports. LADENBURG THALM/SH SH lowered shares of Calithera Biosciences from a buy rating to a neutral rating in a research report on Tuesday, November 15th. SVB Leerink lowered shares of Calithera Biosciences from an outperform rating to a market perform rating in a research report on Tuesday, November 15th.
CALA 一直是其他幾個研究報告的話題。拉登堡 THALM /SH SH 在 11 月 15 日（星期二）的一份研究報告中，將卡利瑟拉生物科學的股份從買入評級降至中性評級。SVB Leerink 降低卡利瑟拉生物科學的股份從一個跑贏大市場上週二的研究報告表現評級, 11 月 15 日.
Calithera Biosciences Stock Performance
卡利瑟拉生物科學股票表現
CALA stock opened at $0.05 on Friday. The firm has a market cap of $258,110.00, a PE ratio of 0.00 and a beta of 1.22. The firm's fifty day moving average is $0.42 and its 200 day moving average is $1.88. Calithera Biosciences has a one year low of $0.05 and a one year high of $13.38.
卡拉股票上週五以 0.05 美元開盤。該公司的市值為 258,110 美元，私募股權比率為 0.00 美元，貝塔值為 1.22 美元。該公司的五十天移動平均線為 0.42 美元，其 200 日移動平均線為 1.88 美元。卡利瑟拉生物科學有一年低點 0.05 美元和一年高點 13.38 美元。
Insider Activity
內幕活動
In other news, Director Deepika Pakianathan sold 121,333 shares of Calithera Biosciences stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $0.39, for a total value of $47,319.87. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.60% of the company's stock.
在其他消息中，董事 Deepika 巴基斯坦人在 1 月 27 日（星期五）的一項交易中出售了卡利瑟拉生物科學股票 121,333 股。這些股票以 0.39 美元的平均價格出售，總價值為 47,319.87 美元。出售在向 SEC 提交的文件中披露，該文件可通過以下方式訪問 證券交易所網站。公司內部人士擁有公司股票的 6.60％。
Institutional Trading of Calithera Biosciences
卡利塞拉生物科學的機構交易
Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its position in shares of Calithera Biosciences by 36.5% in the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock valued at $749,000 after purchasing an additional 496,100 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Calithera Biosciences in the first quarter worth about $404,000. Affinity Asset Advisors LLC purchased a new position in shares of Calithera Biosciences in the first quarter worth about $404,000. Vanguard Group Inc. lifted its stake in shares of Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after buying an additional 26,800 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after buying an additional 72,865 shares in the last quarter. Institutional investors and hedge funds own 33.73% of the company's stock.
一些機構投資者最近修改了他們對該股票的持有量。文藝復興技術有限責任公司增長了其在卡利塞拉生物科學股份的地位 36.5% 在第一季度.文藝復興技術有限責任公司現在擁有 1,853,500 股價值為 749,000 美元的生物技術公司股票後，在此期間額外購買 496,100 股股票。阿麗斯卡投資集團有限責任公司在第一季度收購了卡利瑟拉生物科學股份的新頭寸，價值約為 404,000 美元。親和資產顧問有限責任公司在第一季度購買了卡利瑟拉生物科學股份的新位置，價值約為 404,000 美元。先鋒集團股份有限公司在第三季度將其在卡利塞拉生物科學股份的股份上升了 23.4％。領航集團股份有限公司現在擁有該生物技術公司股票的 141,217 股，價值 415,000 美元，並於上一季度額外購入 26,800 股股票。最後，高盛集團公司在第一季度取消了其在卡利瑟拉生物科學股份的股份 143.2％。高盛集團股份有限公司現在擁有該生物技術公司股票的 123,739 股，價值 50,000 美元，上一季度再購買 72,865 股股票。機構投資者和對沖基金擁有公司股票的 33.73％。
About Calithera Biosciences
關於卡利瑟拉生物科學
(Get Rating)
(取得評分)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Calithera Biosciences, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
- 獲取有關卡利瑟拉生物科學研究報告的免費副本
- 單克隆抗體？狂熱的生物服務在井噴 Q3 上激增 32％
- GitLab 在指導上崩潰; 分析師捍衛
- 股息增加至少 30 年以上的醫療保健股
- 當 SVB 崩潰到灰塵時，Coinbase 持久性有機污染物
- 航空公司更新指南，股票前往不同目的地
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收卡利塞拉生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收有關 Calithera 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。